Multiple Sclerosis Disease length | Age | Informed Consent | Protocol Compliance
Item
confirmed diagnosis of ms, aged 18 - 65 years. duration of disease: >5 years signed, written informed consent willing and able to comply with study visits according to protocol for the full study period
boolean
C0026769 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
C0001779 (UMLS CUI [2])
C0021430 (UMLS CUI [3])
C0525058 (UMLS CUI [4])
Heart failure | Kidney Failure | Liver Failure | Disease At risk Patient | Disease Interferes with Interpretation Research results
Item
patients suffering from significant cardiac, renal or hepatic failure or any other disease that may risk the patient or interfere with the ability to interpret the results
boolean
C0018801 (UMLS CUI [1])
C0035078 (UMLS CUI [2])
C0085605 (UMLS CUI [3])
C0012634 (UMLS CUI [4,1])
C1444641 (UMLS CUI [4,2])
C0030705 (UMLS CUI [4,3])
C0012634 (UMLS CUI [5,1])
C0521102 (UMLS CUI [5,2])
C0459471 (UMLS CUI [5,3])
C0683954 (UMLS CUI [5,4])
Communicable Disease | Chronic infectious disease
Item
patient with any active or chronic infection
boolean
C0009450 (UMLS CUI [1])
C0151317 (UMLS CUI [2])
Organ dysfunction Life Threatening
Item
no life-threatening organ dysfunction.
boolean
C0349410 (UMLS CUI [1,1])
C2826244 (UMLS CUI [1,2])
Pregnancy | At risk Pregnancy
Item
pregnancy or risk of pregnancy.
boolean
C0032961 (UMLS CUI [1])
C1444641 (UMLS CUI [2,1])
C0032961 (UMLS CUI [2,2])
HIV-1 Seropositive | HIV-2 Seropositive | Hepatitis B Surface Antigens Seropositive | Hepatitis C Seropositive
Item
patients who are seropositive for hiv1, hiv2, hepatitis b surface antigen, and hepatitis c
boolean
C0019704 (UMLS CUI [1,1])
C0521143 (UMLS CUI [1,2])
C0019707 (UMLS CUI [2,1])
C0521143 (UMLS CUI [2,2])
C0019168 (UMLS CUI [3,1])
C0521143 (UMLS CUI [3,2])
C0019196 (UMLS CUI [4,1])
C0521143 (UMLS CUI [4,2])
Informed Consent Unable
Item
patients unable to give written informed consent in accordance with research ethics board guidelines
boolean
C0021430 (UMLS CUI [1,1])
C1299582 (UMLS CUI [1,2])
Therapeutic immunosuppression | natalizumab | fingolimod
Item
treatment with any immunosuppressive therapy, including natalizumab and fingolimod, within the 3 months prior to randomization
boolean
C0021079 (UMLS CUI [1])
C1172734 (UMLS CUI [2])
C1699926 (UMLS CUI [3])
Interferon-beta | glatiramer acetate
Item
treatment with interferon-beta or glatiramer acetate within the 30 days prior to randomization
boolean
C0015980 (UMLS CUI [1])
C0289884 (UMLS CUI [2])
Adrenal Cortex Hormones
Item
treatment with corticosteroids within the 30 days prior to randomization
boolean
C0001617 (UMLS CUI [1])
Therapy, Investigational
Item
current treatment with an investigational therapy
boolean
C0949266 (UMLS CUI [1])